About Chase Pharmaceuticals
Chase Pharmaceuticals is a Healthcare company based in United States founded in 2007, and was acquired by Allergan in November 2016. Developer of drugs improve cognition and behavioral symptoms associated with Alzheimers disease. Chase Pharmaceuticals has raised $37.67 million across 7 funding rounds from investors including Cipla, Edmond de Rothschild and Allergan. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its competitors include T3D Therapeutics, Alzheon and Longeveron; 3 of its 3 listed competitors have raised funding.
Company details
Developer of drugs improves cognition and behavioral symptoms associated with Alzheimers disease. The companys candidates include CPC-201, CPC-212, and CPC-250 which are next-generation Acetylcholinesterase inhibitors (AChEI) formulations for the symptomatic treatment of Alzheimers disease.
- Headquarters United States
- Stage Acquired
- SectorsHealthcare
- Website chasepharmaceuticals.com
- Social LinkedIn
- Acquired by Allergan (Nov 2016)
Funding Insights of Chase Pharmaceuticals
Chase Pharmaceuticals has successfully raised a total of $37.67M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $37.67M
- Total Rounds 7
- Investors Count 4
All 7 funding rounds of Chase Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2016 | Series B | β | β | ||
| Mar 2016 | $11.97M | Series B | β | β | β |
| Feb 2016 | $3.5M | Series B | β | Cipla | |
| May 2014 | $21M | Series B | β | New Rhein | |
| Jun 2011 | Series A | β | Brain Trust Accelerator Fund | β | |
| Nov 2010 | $1.2M | Series A | β | β | β |
| Jun 2010 | Series A | β | Brain Trust Accelerator Fund | β |
5 investors in total: 5 institutional.
Investors in Chase Pharmaceuticals
Chase Pharmaceuticals has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Cipla, Edmond de Rothschild and Allergan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are focused on life sciences ventures. | newrhein.com | Philadelphia, USA | ||
Diversified asset management, corporate advisory, and private equity firm focused on multiple sectors | 1953 | edmond-de-rothschild.com | Paris, France | |
Investment fund focused on brain disease diagnosis and treatment. | braintrustvc.com | Burlingame, United States | ||
APIs, generic drugs, and formulation services are manufactured. | 1935 | cipla.com | Mumbai, India | |
A portfolio of generic medicines is developed and manufactured. | 1948 | allergan.com | Madison, United States |
Investor details for Chase Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Chase Pharmaceuticals
4 dated milestones of Chase Pharmaceuticals across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Chase Pharmaceuticals is founded.
- Funding First funding round.
- Funding Latest funding round, Series B,.
- Exit Acquired by Allergan.
Competitors of Chase Pharmaceuticals
Chase Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include T3D Therapeutics, Alzheon and Longeveron.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| t3dtherapeutics.com | 2013 | Durham, United States | $33.02M | Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed. | ||
| alzheon.com | 2013 | Framingham, United States | $195.25M | Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed. | ||
| longeveron.com | 2014 | Miami, United States | $1.05M | 23 | Cellular therapies for aging-related and life-threatening conditions are developed. |
Detailed competitors of Chase Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Chase Pharmaceuticals (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chase Pharmaceuticals
Complete news archive for Chase Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chase Pharmaceuticals
Chase Pharmaceuticals was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Chase Pharmaceuticals is headquartered in United States.
Chase Pharmaceuticals is a funded company, having raised a total of $37.67M across 7 funding rounds to date.
Developer of drugs improves cognition and behavioral symptoms associated with Alzheimers disease. The companys candidates include CPC-201, CPC-212, and CPC-250 which are next-generation Acetylcholinesterase inhibitors (AChEI) formulations for the symptomatic treatment of Alzheimers disease.
Chase Pharmaceuticals's top competitors include Alzheon, Longeveron and T3D Therapeutics.
Chase Pharmaceuticals has 5 investors. Key investors include Cipla, Edmond de Rothschild, Allergan, New Rhein Healthcare Investors, and Brain Trust Accelerator Fund.
Yes. Chase Pharmaceuticals was acquired by Allergan in November 2016.

